VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2021 | FIGHT-202: pemigatinib for FGFR2 altered CCA

Arndt Vogel, MD, PhD, Hannover Medical School, Hannover, Germany, outlines the update in the FIGHT-202 study (NCT02924376) presented at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting. The FIGHT-202 study evaluated pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma (CCA) and it was demonstrated that durable responses and sustained tolerability were obtained in patients receiving pemigatinib for CCA harboring FGFR2 aberrations. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Disclosures

Arndt Vogel, MD has had a speaker, consultancy and advisory role at Amgen, Roche, Bayer, Sanofi, BMS, Lilly, Novartis, EISAI, AstraZeneca, Merck, Incyte, Ipsen, PierreFabre, MSD, Sirtex, BTG, Servier, and Terumo.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter